This is a notice of a conference of significance in the medical cannabis field. The Research Summit will be held on March 22-23 at the Natcher Conference Center on the National Institutes of Health campus in Bethesda, Maryland.
After viewing the advertisement for the event I question the premise, as the cannabinoid system itself has no adverse effects; the phrasing of the event’s summary implies a bias toward finding harm, a charge that Dr. Sanjay Gupta and other have levied against the NIH and NIDA for some time.
The discussions will include a Michigan contingent, as Dr. Christine Rabinak from Wayne State University will participate in the section reserved for Therapeutic Potential: Epilepsy, Multiple Sclerosis, Pain, PTSD/Anxiety.
She was the lead author on a paper published in 2013 regarding marijuana use and PTSD.
www.ncbi.nlm.nih.gov/pmc/articles/PMC3445738/
Marijuana and Cannabinoids: A Neuroscience Research Summit is being convened by the National Institutes of Health (NIH), which will focus on the neurological and psychiatric effects of marijuana, other cannabinoids, and the endocannabinoid system. Both the adverse and the potential therapeutic effects of the cannabinoid system will be discussed. The goal of this summit is to ensure evidence-based information is available to inform practice and policy, particularly important at this time given the rapidly shifting landscape regarding the recreational and medicinal use of marijuana.
The meeting is being sponsored by several NIH Institutes and Centers: the National Institute on Drug Abuse(NIDA); the National Institute on Alcohol Abuse and Alcoholism (NIAAA); the National Center for Complementary and Integrative Health (NCCIH); the National Institute of Mental Health (NIMH); and theNational Institute of Neurological Disorders and Stroke (NINDS).
Speakers:
Understanding the Endocannabinoid System
The Scripps Research InstituteKen Mackie, M.D.
Indiana UniversityDaniele Piomelli, Ph.D., Pharm.D.
University of California, Irvine
Brain Development and Function
University of California, San DiegoKent Hutchison, Ph.D.
University of Colorado BoulderMadeline Meier, Ph.D.
Arizona State University
Psychosis, Addiction, and Alcohol Interactions
Massachusetts General HospitalAlan Budney, Ph.D.
Geisel School of Medicine at DartmouthLarry Parsons, Ph.D.
The Scripps Research Institute
Psychomotor Performance and Detection
National Institute on Drug Abuse
Therapeutic Potential: Epilepsy, Multiple Sclerosis, Pain, PTSD/Anxiety
Stanford UniversityAmy Brooks-Kayal, M.D.
Children’s Hospital ColoradoDavid Gloss, M.D., M.P.H.
Charleston Area Medical CenterAndrea G. Hohmann, Ph.D.
Indiana University
Barth Wilsey, M.D.
University of California, San Diego
Cecilia Hillard, Ph.D.
Medical College of Wisconsin
Christine Rabinak, Ph.D.
Wayne State University
Policy-Related Research
RAND CorporationMark Kleiman, Ph.D., M.P.P.
NYU Marron Institute of Urban Management
Please visit the website for detailed security and location information.
apps1.seiservices.com/nih/mj/2016/Default.aspx
Source: The Compassion Chronicles
